CD33 and acute myeloid leukemia: Partly due to the toxicity, Mylotarg was withdrawn from the U.S. market in 2010 and re-approved by the FDA in 2017 for the treatment of CD33+ AML with a lower recommended dose and a revised treatment schedule [78].